Capstone Investment Advisors LLC Invests $539,000 in Denali Therapeutics Inc. $DNLI

Capstone Investment Advisors LLC bought a new position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) in the 2nd quarter, HoldingsChannel reports. The institutional investor bought 20,964 shares of the company’s stock, valued at approximately $539,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Denali Therapeutics by 4.0% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 88,507 shares of the company’s stock valued at $1,210,000 after buying an additional 3,432 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in shares of Denali Therapeutics by 58.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,672,078 shares of the company’s stock valued at $22,732,000 after buying an additional 614,555 shares during the period. Empowered Funds LLC boosted its stake in shares of Denali Therapeutics by 11.0% in the first quarter. Empowered Funds LLC now owns 20,639 shares of the company’s stock worth $281,000 after buying an additional 2,052 shares during the last quarter. Woodline Partners LP boosted its stake in shares of Denali Therapeutics by 13.5% in the first quarter. Woodline Partners LP now owns 113,517 shares of the company’s stock worth $1,543,000 after buying an additional 13,517 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in Denali Therapeutics by 1.7% during the second quarter. JPMorgan Chase & Co. now owns 191,613 shares of the company’s stock worth $2,681,000 after acquiring an additional 3,210 shares during the period. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Denali Therapeutics

In related news, insider Alexander O. Schuth sold 2,857 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $25.07, for a total value of $71,624.99. Following the completion of the transaction, the insider directly owned 281,763 shares of the company’s stock, valued at approximately $7,063,798.41. This represents a 1.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 9.70% of the company’s stock.

Denali Therapeutics Trading Down 2.7%

DNLI stock opened at $24.00 on Friday. Denali Therapeutics Inc. has a 12-month low of $12.58 and a 12-month high of $27.30. The business’s 50-day moving average is $24.62 and its 200 day moving average is $21.72. The company has a current ratio of 8.37, a quick ratio of 8.32 and a debt-to-equity ratio of 0.01. The stock has a market cap of $3.84 billion, a price-to-earnings ratio of -8.45 and a beta of 1.01.

Denali Therapeutics (NASDAQ:DNLI) last announced its earnings results on Thursday, August 6th. The company reported ($0.68) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.17). The business had revenue of $3.60 million during the quarter, compared to analyst estimates of $2.15 million. During the same period in the prior year, the firm earned ($0.72) earnings per share. On average, sell-side analysts anticipate that Denali Therapeutics Inc. will post -2.67 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts recently weighed in on the company. Morgan Stanley lifted their price target on Denali Therapeutics from $35.00 to $36.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Friday, July 17th. UBS Group lifted their target price on shares of Denali Therapeutics from $25.00 to $34.00 and gave the company a “buy” rating in a report on Friday, August 7th. Wall Street Zen upgraded shares of Denali Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. Finally, B. Riley Financial boosted their target price on shares of Denali Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Tuesday. Fourteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Denali Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $35.85.

Denali Therapeutics Profile

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.